These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34881062)

  • 1. Relugolix: A new kid on the block among gonadotrophin-releasing hormone antagonists.
    Fragkoulis C; Glykas I; Dellis A; Mitsogiannis I; Papatsoris A
    Arab J Urol; 2021; 19(4):460-463. PubMed ID: 34881062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer.
    Saad F; Shore ND
    Ther Adv Med Oncol; 2021; 13():1758835921998586. PubMed ID: 34408793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
    Dearnaley DP; Saltzstein DR; Sylvester JE; Karsh L; Mehlhaff BA; Pieczonka C; Bailen JL; Shi H; Ye Z; Faessel HM; Lin H; Zhu Y; Saad F; MacLean DB; Shore ND
    Eur Urol; 2020 Aug; 78(2):184-192. PubMed ID: 32273183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials.
    Sari Motlagh R; Abufaraj M; Mori K; Aydh A; Rajwa P; Katayama S; Grossmann NC; Laukhtina E; Mostafai H; Pradere B; Quhal F; Karakiewicz PI; Enikeev DV; Shariat SF
    Eur Urol Oncol; 2022 Apr; 5(2):138-145. PubMed ID: 34301529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer.
    Roy S; Zaorsky NG; Bagshaw HP; Berlin A; Tree A; Turner S; Koontz B; Nguyen P; Chen R; Dess RT; Jackson WC; Kishan AU; Stish B; Nagar H; Posadas E; Tran PT; Solanki A; Shore ND; Guo G; Ponsky L; Shoag JE; Morgans AK; Garcia JA; Showalter TN; Feng FY; Spratt DE
    Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):278-289. PubMed ID: 34923058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relugolix: A Review in Advanced Prostate Cancer.
    Shirley M
    Target Oncol; 2023 Mar; 18(2):295-302. PubMed ID: 36652173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer.
    Moussa M; Papatsoris A; Dellis A; Chakra MA; Fragkoulis C
    Expert Opin Pharmacother; 2021 Dec; 22(17):2373-2381. PubMed ID: 34187259
    [No Abstract]   [Full Text] [Related]  

  • 8. Advances with androgen deprivation therapy for prostate cancer.
    Yu EM; Aragon-Ching JB
    Expert Opin Pharmacother; 2022 Jun; 23(9):1015-1033. PubMed ID: 35108137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer.
    De La Cerda J; Dunshee C; Gervasi L; Sieber P; Belkoff L; Tutrone R; Lu S; Gatoulis SC; Brown B; Migoya E; Shore N
    Target Oncol; 2023 May; 18(3):383-390. PubMed ID: 37060432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
    Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer.
    Liu YF; Fu SQ; Yan YC; Gong BB; Xie WJ; Yang XR; Sun T; Ma M
    Drug Des Devel Ther; 2021; 15():639-649. PubMed ID: 33623372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relugolix in the management of prostate cancer.
    Sahu KK; Tripathi N; Agarwal N; Swami U
    Expert Rev Anticancer Ther; 2022 Sep; 22(9):891-902. PubMed ID: 35866612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis.
    Arjona Ferreira JC; Migoya E
    F S Rep; 2023 Jun; 4(2 Suppl):73-82. PubMed ID: 37223761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular Toxicity of Androgen Deprivation Therapy.
    Boland J; Choi W; Lee M; Lin J
    Curr Cardiol Rep; 2021 Jul; 23(8):109. PubMed ID: 34216282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation therapy and side effects: are GnRH antagonists safer?
    Freedland SJ; Abrahamsson PA
    Asian J Androl; 2021; 23(1):3-10. PubMed ID: 32655041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.
    Boccon-Gibod L; van der Meulen E; Persson BE
    Ther Adv Urol; 2011 Jun; 3(3):127-40. PubMed ID: 21904569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
    Spratt DE; Dorff T; McKay RR; Lowentritt BH; Fallick M; Gatoulis SC; Flanders SC; Ross AE
    Future Oncol; 2024 Apr; 20(12):727-738. PubMed ID: 38488039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy.
    Tatenuma T; Miyamoto H
    Drug Des Devel Ther; 2023; 17():2325-2333. PubMed ID: 37559910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cardiovascular side effects in patients undergoing androgen deprivation therapy: superiority of gonadotropin-releasing hormone antagonists? An update].
    von Amsberg G; Thiele H; Merseburger A
    Urologe A; 2021 Nov; 60(11):1450-1457. PubMed ID: 34213627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.